STOCK TITAN

TWST insider filings: 2,716-share sale after restricted stock vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

The Form 144 filed for TWST reports a proposed sale of 2,716 shares of common stock through Fidelity Brokerage Services on 08/21/2025 with an aggregate market value of $70,518.77. The shares were acquired on 08/20/2025 via restricted stock vesting from the issuer and payment is noted as compensation. The filing also lists five sales by Emily M. Leproust in the past three months totaling 12,711 shares with combined gross proceeds of $398,886.65 on dates from 05/21/2025 through 08/04/2025. The notice includes the standard signature representation about absence of undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Notice documents a small proposed sale following restricted stock vesting and multiple recent disposals by the same seller.

The filing shows a proposed sale of 2,716 shares acquired one day earlier by restricted stock vesting and designated as compensation. The seller, Emily M. Leproust, completed five prior sales in the preceding three months totaling 12,711 shares and roughly $398,887 in gross proceeds. Relative to the reported outstanding share count of 60,360,925, these transactions represent a de minimis percentage of outstanding stock. From a market-impact perspective the sizes are small; the filing primarily serves regulatory disclosure of intended insider sales under Rule 144.

TL;DR: Form 144 furnishes required disclosure for proposed Rule 144 sales tied to recently vested restricted stock.

The document provides required particulars: broker, share counts, acquisition date and nature (restricted stock vesting), and prior sales in the three‑month lookback. It includes the signer’s representation about lack of undisclosed material adverse information. The filing appears to meet the informational elements expected for a Rule 144 notice; no regulatory deficiencies are stated within the text provided.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TWST Form 144 propose to sell?

The notice proposes to sell 2,716 shares of TWST common stock through Fidelity on 08/21/2025 with an aggregate market value of $70,518.77.

How were the shares being sold on Form 144 acquired?

The shares were acquired on 08/20/2025 via restricted stock vesting from the issuer, and the payment nature is listed as compensation.

Who sold shares of TWST in the past three months and how many?

Emily M. Leproust sold 12,711 shares during the past three months on five dates (05/21/2025, 06/06/2025, 06/20/2025, 07/02/2025, 08/04/2025) for combined gross proceeds of $398,886.65.

Through which broker is the proposed sale to occur?

The proposed sale is to occur through Fidelity Brokerage Services LLC, with the filing listing an address at 900 Salem Street, Smithfield, RI.

What outstanding share count is reported in the filing?

The filing reports 60,360,925 shares outstanding for the issuer.
Twist Bioscience

NASDAQ:TWST

TWST Rankings

TWST Latest News

TWST Latest SEC Filings

TWST Stock Data

2.77B
60.26M
1.86%
115.89%
16.96%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO